Literature DB >> 24485472

Anxiolytic function of the orexin 2/hypocretin A receptor in the basolateral amygdala.

David H Arendt1, James Hassell2, Hao Li2, Justin K Achua3, Douglas J Guarnieri4, Ralph J Dileone4, Patrick J Ronan5, Cliff H Summers6.   

Abstract

The orexin/hypocretin system interacts with many of the same circuitries contributing to stress-associated disorders like depression and anxiety. These include potentially reciprocal connections with corticotropin releasing factor (CRF) neurons which drive the hypothalamic-pituitary-adrenal (HPA) endocrine response in addition to having an anxiogenic effect in the central amygdala (CeA). Antagonism of the orexin type 1 receptor (Orx1) in the hypothalamus has also been shown to block panic attacks. However, few studies have investigated the effect of orexinergic signaling in the basolateral amygdala (BLA) which is responsible for contextual fear, and modulates the activity of the CeA. To this end, we chronically stressed c57bl/6 mice with social defeat and examined the gene expression of the orexin receptors in the BLA. We found that the transcripts for the Orx1 and Orx2 receptors diverged in the BLA with Orx1 increasing and Orx2 decreasing in animals that were susceptible to the chronic defeat. These changes were not seen in the prelimbic cortex (PrL) which sends efferents to the BLA. We then tried to recapitulate these expression patterns in the BLA using short hairpin interfering sequences delivered by adeno-associated viruses to knock down the orexin receptors. While the Orx1 knockdown did reduce locomotor activity, it did not decrease depressive or anxious behaviors. Knocking down the Orx2 receptors in the BLA increased anxious behavior as measured by reduced social preference and reduced time spent in the center of an open field. Due to the divergent expression patterns of the two receptors in response to chronic stress, orexinergic activity in the BLA may be responsible for bidirectional modulation of anxious behavior. Furthermore, these data raise the possibility that an Orx2 agonist may serve as an effective means to treat anxiety disorders.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amygdala; Anxiety; Basolateral amygdala; Hypocretin; Knockdown; Orexin; Orexin 2 receptor; shRNA

Mesh:

Substances:

Year:  2013        PMID: 24485472      PMCID: PMC4361941          DOI: 10.1016/j.psyneuen.2013.10.010

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  51 in total

1.  Attenuated defense response and low basal blood pressure in orexin knockout mice.

Authors:  Yuji Kayaba; Akira Nakamura; Yoshitoshi Kasuya; Takashi Ohuchi; Masashi Yanagisawa; Issei Komuro; Yasuichiro Fukuda; Tomoyuki Kuwaki
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2003-05-15       Impact factor: 3.619

2.  Local gene knockdown in the brain using viral-mediated RNA interference.

Authors:  Jonathan D Hommel; Robert M Sears; Dan Georgescu; Diana L Simmons; Ralph J DiLeone
Journal:  Nat Med       Date:  2003-11-23       Impact factor: 53.440

3.  Excitatory action of hypocretin/orexin on neurons of the central medial amygdala.

Authors:  A Bisetti; V Cvetkovic; M Serafin; L Bayer; D Machard; B E Jones; M Mühlethaler
Journal:  Neuroscience       Date:  2006-09-22       Impact factor: 3.590

4.  Orexin signaling via the orexin 1 receptor mediates operant responding for food reinforcement.

Authors:  Ruth Sharf; Maysa Sarhan; Catherine E Brayton; Douglas J Guarnieri; Jane R Taylor; Ralph J DiLeone
Journal:  Biol Psychiatry       Date:  2010-02-26       Impact factor: 13.382

5.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

Review 6.  Neuroanatomy of anxiety.

Authors:  Newton Sabino Canteras; Leonardo Barbosa Resstel; Leandro José Bertoglio; Antonio de Pádua Carobrez; Francisco Silveira Guimarães
Journal:  Curr Top Behav Neurosci       Date:  2010

7.  Orexin signaling mediates the antidepressant-like effect of calorie restriction.

Authors:  Michael Lutter; Vaishnav Krishnan; Scott J Russo; Saendy Jung; Colleen A McClung; Eric J Nestler
Journal:  J Neurosci       Date:  2008-03-19       Impact factor: 6.167

8.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

9.  Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system.

Authors:  Shyeilla V Dhuria; Leah R Hanson; William H Frey
Journal:  J Pharmacol Exp Ther       Date:  2008-10-22       Impact factor: 4.030

10.  Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system.

Authors:  Shyeilla V Dhuria; Leah R Hanson; William H Frey
Journal:  J Pharm Sci       Date:  2009-07       Impact factor: 3.534

View more
  25 in total

Review 1.  Evidence for the role of corticotropin-releasing factor in major depressive disorder.

Authors:  R Parrish Waters; Marion Rivalan; D A Bangasser; J M Deussing; M Ising; S K Wood; F Holsboer; Cliff H Summers
Journal:  Neurosci Biobehav Rev       Date:  2015-08-10       Impact factor: 8.989

2.  Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression.

Authors:  Clarissa D Staton; Jazmine D W Yaeger; Delan Khalid; Fadi Haroun; Belissa S Fernandez; Jessica S Fernandez; Bali K Summers; Tangi R Summers; Monica Sathyanesan; Samuel S Newton; Cliff H Summers
Journal:  Neuropharmacology       Date:  2018-09-18       Impact factor: 5.250

Review 3.  Nuance and behavioral cogency: How the Visible Burrow System inspired the Stress-Alternatives Model and conceptualization of the continuum of anxiety.

Authors:  James M Robertson; Melissa A Prince; Justin K Achua; Russ E Carpenter; David H Arendt; Justin P Smith; Torrie L Summers; Tangi R Summers; Cliff H Summers
Journal:  Physiol Behav       Date:  2015-07-01

4.  The hypocretin/orexin system mediates the extinction of fear memories.

Authors:  África Flores; Victòria Valls-Comamala; Giulia Costa; Rocío Saravia; Rafael Maldonado; Fernando Berrendero
Journal:  Neuropsychopharmacology       Date:  2014-06-16       Impact factor: 7.853

5.  Brain 5-HT deficiency increases stress vulnerability and impairs antidepressant responses following psychosocial stress.

Authors:  Benjamin D Sachs; Jason R Ni; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-09       Impact factor: 11.205

Review 6.  The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse.

Authors:  Morgan H James; Jennifer E Fragale; Shayna L O'Connor; Benjamin A Zimmer; Gary Aston-Jones
Journal:  Neuropharmacology       Date:  2020-10-19       Impact factor: 5.250

Review 7.  Hypocretin (orexin) neuromodulation of stress and reward pathways.

Authors:  William J Giardino; Luis de Lecea
Journal:  Curr Opin Neurobiol       Date:  2014-07-20       Impact factor: 6.627

8.  Involvement of the orexin/hypocretin system in the pharmacological effects induced by Δ(9) -tetrahydrocannabinol.

Authors:  África Flores; Marina Julià-Hernández; Rafael Maldonado; Fernando Berrendero
Journal:  Br J Pharmacol       Date:  2016-03-03       Impact factor: 8.739

Review 9.  Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.

Authors:  Ying Han; Kai Yuan; Yongbo Zheng; Lin Lu
Journal:  Neurosci Bull       Date:  2019-11-28       Impact factor: 5.203

Review 10.  Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: Potential for therapy.

Authors:  Cliff H Summers; Jazmine D W Yaeger; Clarissa D Staton; David H Arendt; Tangi R Summers
Journal:  Brain Res       Date:  2018-12-24       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.